Early transfusion of high ratio of fresh frozen plasma (FFP) and red blood cells (RBC) is associated with mortality reduction. However, time to reach high ratio is limited by the need to thaw the FFP. French lyophilized plasma (FLYP) used by French army and available in military teaching hospital does not need to be thawed and is immediately available. We hypothesize that the use of FLYP may reduce time to reach a plasma/RBC ratio of 1:1.
H
emorrhage is the leading cause of death for severe trauma patients, accounting for approximately 30% of deaths within the first 24 h after injury. 1, 2 Acute traumatic coagulopathy increases threefold the risk of death. 3, 4 It is now widely accepted that its early diagnosis and treatment are essential to improve prognosis. 5, 6 During the first hour after trauma, coagulopathy and thrombocytopenia occur in almost 25% of severe trauma patients. 3, 4 When these patients are transfused efficiently with a high ratio of plasma, mortality is reduced. 6 Early balanced transfusion ratio of plasma to packed red blood cells (RBCs) of 1:1 or 1:2 is part of the initial strategy to treat traumatic coagulopathy, associated with limited vascular filling to limit coagulation factor dilution. [6] [7] [8] [9] [10] This strategy combined with permissive hypotension defines the damage control resuscitation (DCR). 6 DCR has been reported to reduce mortality in severe trauma patients. 8 The early administration of high plasma/RBC ratio is a key element to improve the efficacy of transfusion. The PROPPR clinical trial reported a reduction in deaths caused by hemorrhage when high plasma/RBC ratio was administered. Patients in the high-ratio group received rapidly plasma (less than 10 min after admission for the six centers participating in the trial), which could have been a bias influencing this reduction. 10 Plasma used in French trauma centers is fresh frozen plasma (FFP) and the time to administrate FFP is limited by the incompressible thawing time of 20 min. 8 One solution is to thaw the plasma before the patient arrives. Some American trauma centers therefore have implemented a massive transfusion protocol with a permanent stock of thawed plasma to reduce the time required until the first transfusion of plasma. 8, 11 This strategy has reduced the waiting time from 95 min to 42 min and has therefore led to a reduction in mortality. 12 French Army Health Service has used dried plasma, the French lyophilized plasma (FLYP), for years. This plasma is produced in France by the French Military Blood Institute (Centre de transfusion sanguine des armées [CTSA] ) and is available for French Role 2 support at deployed medical facilities. The French Role 2 is a mobile surgical structure deployed during military operations. It has three tents to admit wounded war patients (French or allies military, civilian) and perform DCR. It is equipped to perform surgical procedures, emergency diagnostic procedures (x-ray machine, ultrasound machine, laboratory for limited blood analysis), and transfusion management. FLYP's physical properties allow to stock it at room temperature for 2 years without coagulation factor deterioration. The in vitro hemostatic properties of FLYP are comparable to those of FFP. 13, 14 It can be reconstructed in less than 10 min and has the potential to reduce the time to plasma transfusion in severe trauma patients. It has been available in French military hospitals and used in daily traumatology practice since 2013.
We hypothesized that FLYP transfusion would reduce the delay to obtain a plasma/RBC ratio of 1:1. The principal aim of this study was to compare the FFP transfusion time to the FLYP transfusion time.
MATERIALS AND METHODS

Ethics Committee
The Sainte-Anne Military Hospital (SAMH) Ethics Committee approved this study. 
Study Framework
A retrospective study was performed at SAMH over a period of 48 months (January 1, 2012 to December 31, 2015). SAMH is a Level 1 trauma center in the Var, France (Department 83).
The hospital has two resuscitation rooms located in the emergency department (ED) that are specially adapted to treat severe trauma patients and have state-of-the-art equipment for interventional radiology, surgery (thoracic, visceral, orthopedic, and neurosurgery), and laboratory.
A trauma leader coordinated admission of severe trauma patients. The multidisciplinary team consisted of an anesthesiologist/critical care specialist, a general surgeon, an emergency physician, and nurses. A Focused Assessment with Sonography for Trauma (FAST) was always performed, completed with a biological assessment and standard x-rays of the chest and pelvis. A blood typing was immediately sent to the CTSA after the first blood test performed in the ED.
CTSA manages blood products, provision of transfusion advice permanently, hemovigilance, and blood traceability. 14 FLYP is stored in CTSA and is delivered immediately if needed. It can be reconstituted in the ED. FFP need to be thawed in CTSA before its delivery.
Massive transfusion protocol (MTP) was activated when the trauma patient presented hemodynamic instability associated with clinical bleeding. When the MTP was activated, a transfusion pack was immediately available including two RBC O− delivered to the patient's bedside before his arrival; six RBC and six FFP were prepared. SAMH has been authorized to use FLYP since June 1, 2013. Since the decision of the French military institution, two FLYP were systematically delivered with the two RBC O− and immediately available at the trauma patient's arrival in the resuscitation room. FLYP were initially reconstituted and used in the resuscitation room for early plasma transfusion, and then FFP were the standard plasma used for the transfusion management in OR and intensive care unit.
The management was in line with the DCR strategy. The trauma leader started blood product transfusion when the patient presented hemodynamic instability (SPB < 90 mm Hg and/or heart rate > 120 c/min and/or Hb < 10 g/dL) associated with clinical or echographic bleeding. Vasopressors were introduced to maintain target arterial pressure (SPB of 80-90 mm Hg except for cranial trauma patients).
Tranexamic acid first dose was administrated by the prehospital team or in the ED according to the guidelines.
Fibrinogen concentrate could be transfused when active clinical or biological bleeding persisted and/or plasma fibrinogen level was less than 1.5 g/dL.
Population
We included all severe trauma patients who required at least transfusion of 2 U of RBC in the ED. 
Data Collected and Definitions
We collected demographic data from the SAMH severe trauma registry since January 2012. The data included age, time of prehospital team arrival on scene, time of arrival at SAMH ED, injury, number of RBC units, plasma and platelet units transfused, time to transfusion of RBC and plasmas, and standard blood test.
Coagulopathy was defined as prothrombin time (PT) <70% and/or a platelet count <100,000/mm 3 .
The following scores were calculated: revised trauma score (RTS), trauma associated severe hemorrhage (TASH) score, and injury scale score (ISS). RTS is a physiology-based scoring system predicting death risk. It incorporates initial Glasgow Coma Scale score, SBP, and respiratory rate. Each value ranges from 4 (normal) to 0 (poor) (yielding a high of 7.841 and a low of 0). 12 TASH score evaluates the risk of trauma to be associated to severe hemorrhage requiring massive transfusion. These values are gender, SBP, heart rate, Hb, base excess, positive FAST, unstable pelvic fracture, and open or dislocated femur fracture. Each factor described above has several answer choices that weigh a different number of points. The overall score is obtained by adding the points together. TASH score >18 represents a massive transfusion probability >50%. 13 Abbreviated Injury Scale (AIS) is an anatomic injury scoring system that quantifies injuries in various body regions from a score of 1 (minor injury) to 6 (nonsurvivable). A patient's Injury Severity Score (ISS) is calculated by summing the squares of the three highest AIS scores in three different body regions (values range from 1 to 75). 12 The results of the various radiologic and sonographic examinations were also collected: a positive sonography for trauma (FAST) in case of intra-abdominal and/or intra-pleural effusion and/or pneumothorax, positive pulmonary radiography in case of pleural effusion and/or pneumothorax, and positive pelvic radiography in case of pelvic fracture.
Transfusion data during the 24 h in ED, operating room, and ICU were extracted from the patient transfusion registry. We counted the 24 h since the patient arrived at hospital.
We defined a massive transfusion for more than 10 U of RBC in the first 24 h and critical transfusion for more than 4 U of RBC at least 1 hour during the first 24 hours after admission. 10 
Statistical Analysis
The distribution of quantitative variables was determined by the Shapiro-Wilk test. The mean ± SD represented the variables with a normal distribution. Those without a normal distribution were expressed as medians with interquartile ranges (25th and 75th). Quantitative variables were compared by MannWhitney test. Qualitative data were expressed as absolute value and percentage. Comparisons were performed using Fisher's exact test. Statistical significance was defined as p < 0.05.
Statistical analysis was performed with XLSTAT version 2017.18.07 (Addinsoft).
RESULTS
Patient Inclusion
Between January 1, 2012 and December 31, 2015, 1,191 severe trauma patients were admitted in our structure. Among them, 72 had transfusion of at least 2 U of RBC in ED. All patients received at least 1 U of plasma. The first plasma transfused was FFP for 29 patients and FLYP for 43 patients.
Patients' Characteristics
Patients' characteristics are presented in Table 1 . Time to arrive to hospital was significantly higher in the FLYP group than in the FFP group with respectively a median of 102 min (IQR 48, 128) versus 70 min (IQR 56, 105) (p = 0.024). There was no difference in tranexamic acid use between the two groups. There was no difference in duration time in ED. There was no difference in TASH scores and RTS. The median thorax AIS score was statistically higher in the FLYP group. There was no significant difference in the other AIS (head, abdomen, pelvis) or ISS.
Clinical and biological data on ED admission are presented in Table 2 . There was no significant difference in the number of patients presenting an Hb <11 g/dL: 23 (74%) versus 32 (66%) (p = 0.632) in the FLYP and FFP groups, respectively. There was no difference in TP, platelet count, and fibrinogen concentration between the two groups. Coagulopathy was present at admission in 100% of patients.
Biological data at 3 h and 24 h of admission are presented in Table 2 . There was no difference in Hb, TP, platelet count, and fibrinogen concentration between the two groups.
Transfusion Data
The median time until the first transfusion of RBC was similar in both groups. The time until the first transfusion of plasma was significantly shorter in the FLYP group with a median of 15 min (IQR 10-25) versus 95 min (IQR 70-145) in the FFP group (p < 0.001) ( Table 3 ). There was no difference in the first time of fibrinogen concentrate transfusion, in the FLYP group a median of 65 min (IQR 50-75) versus 68 min (IQR 55-78) in the FFP group (p = 0.772).
Time until a 1:1 ratio was shorter in the FLYP group than in the FFP group (Fig. 1) .
The number of RBCs transfused in the 24 h was significantly lower in the FLYP group. There was no significant difference in the total number of transfusions in the first 24 h of plasma, fibrinogen, or platelets.
The number of patients requiring massive and critical transfusions was significantly lower in the FLYP group.
Prognosis and Mortality at 24 h
There was no significant difference in the hospital length of stay with a median of 13 days (IQR 1-46) for the FFP group and 18 days (IQR 10-38) for the FLYP group, or in the ICU length of stay with a median of 3 days (IQR 1-18) for the FFP group and 8 days (IQR 2-15) for the FLYP group.
There was no significant difference in mortality at 24 h or in the causes of death. Mortality linked to hemorrhagic causes was 17% in the FFP group versus 7% in the FLYP group (p = 0.293). Mortality resulting from refractory intracranial hypertension (IH) was of 14% of the cases in both groups (p = 0.855).
DISCUSSION
Our study showed that the use of FLYP reduced time to the first plasma transfusion from 95 min to 15 min, which enabled an early plasma/RBC ratio close to 1:1 (Fig. 1) . High plasma/RBC ratios have shown to decrease mortality by hemorrhage in trauma patients. Recent published data have demonstrated that adherence to these recommendations was associated with better patient survival. 15 Our results are in agreement with the literature concerning the delay to administrate the first FFP, 95 min in our study. 8, 12 This delay is explained by the need to thaw the plasma before use.
The French Military Blood Institute has produced FLYP since 1949. Its use is controlled by French government guidelines. 16 It is produced with a pool of deleucocyted plasma donors.
14 A photochemical pathogen inactivation process (amotosalen) has eliminated the risk of infection since 2010. FLYP is compatible with all blood groups, can be stored at room temperature for 2 years, and can be reconstituted in less than 10 min, making it a product that is particularly adapted to overseas military operations. French hemovigilance data are collected since 1994 including FLYP and no infectious complication has been reported. Its in vitro hemostatic properties are close to those of FFP providing an equivalent level of coagulation factors. 18 Current clinical and biological data have confirmed the safety of FLYP.
14 FLYP has been used for many years on the battlefield for Role 2 support for hemorrhagic shock in wounded soldiers. 17 It is also available for medical evacuation teams on battlefields to administer plasma before Role 2 admission to complement tranexamic acid. 17 However, to date, no study has reported the use of FLYP in civilian trauma patients.
A perspective of prehospital use in civilian context will be interesting. Our study showed that trauma patients with hemorrhagic shock presented already at the ER admission an important coagulation disorder. The FLYP permits, with its storage and rapid reconstitution conditions, a rapid plasma administration to treat an early traumatic coagulopathy. Sunde et al. describe in a small retrospective study that introduction of freeze-dried plasma (FDP) in civilian Helicopter Emergency Medical Service seems feasible and may be safe. 19 Further prospective studies are needed to clarify the role of FDP in civilian prehospital hemorrhagic shock resuscitation.
It was previously shown the benefit of early plasma transfusion concerning the reduction in RBC transfusion, which was also the case in our work. 12 In fact, we observed a reduction in the use of RBC in the first 24 h and less requirement to massive and critical transfusions in patients who benefited from FLYP. In literature, a massive transfusion protocol that anticipates the early use of plasma is associated with a reduction in mortality.
9,12 Nevertheless, we did not find in our study any significant reduction of mortality probably owing to the small population Time to first unit was defined as the time from arrival at our trauma center to the time the first unit was administered. Massive transfusion was defined as ten or more units of RBC in the first 24 h after injury. Critical transfusion was defined as 4 or more units of RBC at least 1 h during the first 24 h after admission.
RBC, red blood cells. and to the significant proportion of head trauma patients with refractory IH.
Severe head trauma was defined by GSC <9 with CT-scan injuries. The management aims of bleeding and coagulopathy concerning patients with severe trauma brain injury are slightly different. 7 It is actually recommended: Hb ≥10 g/dL, PT ≥70%, platelet ≥100 G/L, and fibrinogen ≥2 g/L. 7 Our practice did not change during the study. These targets require a more important blood product transfusion. In our study, the head trauma proportion and severity were the same and did not impact the group comparison.
Our study showed that the use of FLYP is associated with rapid plasma administration in hemorrhagic trauma patients and a rapid 1:1 plasma/RBC ratio. It seems to be a valuable alternative to FFP, which is administered with a longer delay if the plasma has not been thawed before the patient's admission. The risk also may be a waste of a precious resource if the plasma is thawed before the patient's arrival and finally not necessary.
We did not find any difference in the rate of coagulopathy correction between the two groups at 3 and 24 h after admission. This could be explained by the absence of early coagulation results. The absence of standardized coagulation control protocol did not allow us to evaluate an early coagulopathy improvement in the first hour of management. Nevertheless, it would seem likely that an early plasma transfusion by FLYP would permit initial control of traumatic coagulopathy.
Our study presents limits linked to the retrospective design. First, we observed differences in severity among the patients even if they were not statistically significant. However, they were unfavorable for the FLYP group with longer preadmission time and higher chest AIS score. Time to reach hospital was longer in the FLYP group. This reflects a change and improvement in the prehospital triage of severe trauma patients. The FIRST study has demonstrated a substantially lower risk of death when major trauma care is provided in a dedicated trauma center instead of a general hospital. 20 SAMH is the only Level 1 trauma center in the department of VAR. When the place of the accident was distant from the SAMH, severe trauma patients were transferred to the nearest hospital. Since FISRT, despite the distance and the prehospital travel time, every severe trauma patient was transferred and managed in the SAMH. Second, comparison of two consecutive treatment periods in a trauma center can create a bias linked to the team's learning curve. Patients who received FLYP were treated during a period after those who received FFP, a period in which the trauma center team could have improved its practice and expertise. This was well demonstrated in the Nathens study. 21 However, considering markers showing team expertise, we did not find any difference in the time spent in ED. Moreover, we did not observe time difference of the first transfusion in fibrinogen concentrate, as the massive transfusion protocol and hemorrhagic shock treatment strategy were available since 2011 in our trauma center. All our patricians have military expertise and trauma experience; the DCR and damage control surgery strategies were the same and applied throughout the study period. There has been no change in strategy particularly in the massive transfusion management except for the use of FLYP since June 1, 2013 to improve the first plasma transfusion time.
Actually, FDP products are available in France, Germany, South Africa, and a limited number of other countries. However, no product is available in the USA. 22 Since 2007, the German Red Cross produces LyoPlas N-w, which is quarantined single-donor plasma from male donors or donors tested negative for human leukocyte antigen antibodies, ABO type specific. Since 1996, the National Bioproducts Institute (South Africa) produces Bioplasma FDP, a pooled, spray dried, ABO-universal lyophilized plasma. FLYP is currently available to the US Special Operations Forces under an agreement between the US and French Governments. 21 However, clinical data regarding field and civilian use of all FDP preparations are limited. 23 Finally, our study suggests that French lyophilized plasma could be an interesting alternative to FFP in the early course of transfusion in hemorrhagic trauma patient. We found that the early 1:1 plasma/RBC ratio permitted by the FLYP was associated with a reduction in massive transfusion requirement. These results should be confirmed by a prospective and randomized trial. AUTHORSHIP C.N. wrote the paper. J.B., P.-J.C., P.E., M.C., and Q.M. managed the data collection and governance of the study. All the authors have contributed to the writing of the manuscript and have approved the final manuscript. J.B. and E.M. designed the study. C.N. conceived the study and is its guarantor.
